echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Deqi Pharmaceuticals is officially listed on the Hong Kong Stock Exchange today, holding 12 innovative drugs for the future

    Deqi Pharmaceuticals is officially listed on the Hong Kong Stock Exchange today, holding 12 innovative drugs for the future

    • Last Update: 2020-11-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 20, Deqi Pharmaceuticals was officially listed on the Hong Kong Stock Exchange, becoming the third Hong Kong-share IPO this month and the 12th successfully listed innovative pharmaceutical company this year.
    the company filed for an IPO on the Hong Kong Stock Exchange in August under Chapter 18A of the Main Board Listing Rules, with Goldman Sachs and JPMorgan As co-sponsors.
    images are derived from the offering of 154 million shares at a price of HK$18.08 per share, of which 90 per cent were rights issued and 10 per cent were public offerings, resulting in a net proceeds of about HK$2,636 million. Founded in 2016,
    Deqi Pharmaceuticals is an Asia-Pacific clinical phase biopharmaceutical company focused on innovative anti-tumor drugs dedicated to developing and commercializing the world's first, only and best-in-class therapies to provide safe and effective treatment solutions and improve patient living standards for patients worldwide.
    in the pharmaceutical bio-B shares of the moment, Deqi pharmaceutical is obviously also the capital of the "scent."
    the public offering of Deqi Pharmaceuticals received 229,916 valid subscriptions and was eventually oversubscribed by 264.76 times, well above the previous figure of 52.4 times oversubscribed by Rongchang Bio.
    raised HK$2.636 billion, more than half of the All-Star Cornerstone's subscription to the IPO four months ago, and Deji Pharmaceuticals had just completed a $970 billion round of C financing.
    Although the company has not yet developed products on the clinical, no production capacity, no sales force, but four rounds of financing in four years, the total amount of financing of $578 million, but revealed the market's favor for the company.
    addition, the IPO's strong investor portfolio also shows that Deqi Pharmaceuticals is "not simple."
    Before its official launch, Deki Pharmaceuticals attracted biotech professional investors including Fidelity Investments, GIC Singapore Investment Corporation, BlackRock, Boyu Capital, Sequoia Capital, and biotech professionals such as Cormorant, Octagon and Laurion. The 10 star institutions, the cornerstone line-up, together subscribed for a total of US$179.4 million (HK$1.39 billion in contracts), accounting for 53.25 per cent of the shares sold, with a six-month ban.
    , Fidelity Investments, which is less of a cornerstone investor, has subscribed for a total of $70m, or 19.47 per cent.
    's favor has nothing to do with Deki Pharmaceuticals' excellent global development and commercialization of anti-tumor drugs. Dr. Jianming Mei, founder and CEO of
    , has over 25 years of experience in cancer research and clinical drug development, has worked as a researcher at the National Cancer Center in the United States, and has worked on the development of anti-tumor clinical drugs at companies such as Johnson and Johnson, Novarma and Xinji.
    , Dr. Mei Jianming has published more than 70 books and holds a number of patents with other inventors.
    Chief Commercial Officer John Chin has worked in the pharmaceutical industry for 30 years, having held senior positions at Shishi Meishi, Avant and Xinji, successfully leading the listing of several cancer drugs in the United States, Latin America and China.
    Chief Financial Officer, Mr. Long Zhenguo, has 16 years of experience in investment banking and the stock market, has served in prestigious positions at Goldman Sachs, BFAM Partners and other prestigious institutions, and has led a number of investments in various industries, including healthcare and biotechnology.
    In addition, Chief Operating Officer Liu Yiteng has more than 10 years of experience in multinational operations, Vice President Yang Yijun has worked at Harvard University and a number of global pharmaceutical companies, and another Group Vice President, Dr. Zhai Zhihuan, has worked in the pharmaceutical industry for more than 20 years... Senior team for Deqi pharmaceutical product research and development and commercialization to add a lot of protection.
    12 innovative drugs in hand, the focus of the field of oncology in the global drug market, the field of oncology medicine has been a must-win for pharmaceutical companies.
    the global cancer drug market has grown from $83.2 billion in 2015 to $143.5 billion in 2019 and is expected to reach $244.4 billion in 2024, according to Frost Sullivan.
    , the potential of China's oncology market will be fully stimulated, with its share of the global market expected to increase from 18.4 per cent in 2019 to 24.5 per cent in 2030.
    images from the prospecto, however, the huge gap in cancer treatment at home and abroad highlights the cancer treatment gap that needs to be filled urgently in China.
    compared with developed countries, China's cancer treatment program is still relatively backward, in 2019 traditional chemotherapy methods accounted for 72.6% of China's tumor market, the same period chemotherapy in the global market accounted for only 17.1%, while domestic pharmaceutical companies in generic drugs and RAW drug investment bias also shows that China's cancer treatment still has a huge space for innovation.
    of course, innovative drug research and development is a "nine-dead life" process, how to build products faster and better is related to the survival of enterprises.
    In this regard, Deki Pharmaceuticals uses a "combined, complementary" research and development strategy that will help the company maximize its ability to co-ordinate pipeline assets internally and identify and potential risks earlier in the development of innovative therapies. The
    prospecto shows that by effectively utilizing resources, building partnerships with other pharmaceutical and biotechnology companies, and with outstanding capabilities in target selection, drug research and development differentiation strategies, Dechi Pharmaceuticals has established an innovative research and development pipeline of 12 clinical and preclinical assets.
    addition to the two products progress faster, has entered the clinical 2/3 stage, the rest of the products are mostly in the pre-clinical stage.
    authorized the introduction of the main, 2 products into the clinical late Deqi pharmaceutical most products are licensed to introduce the way.
    , however, the company's products focus on new targets or mechanisms of action, so the tracks are not congested and have the potential to address significant and unseeded medical needs.
    Images from the core product of the prospectus, ATG-010 (selinexor), is the first of its kind and the only SINE compound of its kind to be globally recognized as a globally recognized XPO1 target (critical nuclear output protein) and the only oral therapy approved by the FDA for the treatment of recurring or refractic multiple myeloma and recurring or refractic large B-cell lymphoma.
    ATG-010 and ATG-016 and ATG-527 are three SINE compounds obtained by Deqi Pharmaceuticals from Karyopharm, which can be easily combined with existing standard therapies to treat multiple types of malignancies and generally exhibit good tolerance in clinical trials.
    currently, Deqi Pharmaceuticals is conducting two Phase 2 registered clinical trials in China on ATG-010 for the treatment of MM and R/R DLBCL, and plans to submit both adaptive NDAs in China.
    August, Deki Pharmaceuticals applied to the State Drug Administration for a Phase I/II clinical trial of ATG-016 (eltanexor) for the treatment of HR-MDS patients after demethylation therapy failed.
    , there are only five SINE compounds in clinical development worldwide, of which only three are used for oncology, and the market potential is huge.
    another core product, ATG-008 (onatasertib), developed and licensed by Celgene, has the potential to become the first of its kind to target both mTORC1 and mTORC2, inhibit tumor cell proliferation and induce its apoptosis.
    third-party preclinical studies have shown that the efficacy of the dual-target ATG008 inhibitor mTOR signaling path is more significant than that of traditional mTORC1 inhibitors such as Ivemos and Siromos.
    market for mTORC1/2 inhibitors is very broad, and according to Frost Sullivan, the Size of the Chinese market will reach RMB 5.8 billion by 2030.
    is currently conducting three Phase I/II clinical trials of ATG-008, and if the product comes out, it will bring considerable benefits to the company.
    4 products enter early clinical, many products are in the preclinical stage in addition to ATG-010 and ATG-008, Deqi Bio has 4 products in the early clinical stage.
    SINE compound ATG-016 demonstrated good efficacy and controlled safety in phase 1/2 trials, and is expected to achieve higher frequency administration and long-term drug exposure at high concentrations.
    september this year, Deqi Pharmaceuticals in China submitted a clinical trial of the new ATG-016 drug has been accepted.
    another SINE compound, ATG-527, is a non-tumor drug, an anti-inflammatory and antiviral drug for systemic lupus erythematosus (SLE), chronic active EBV infection (AEBV).
    Pharmaceuticals is planning to conduct clinical trials in China on ATG-527 for patients with CAEBV infection.
    ATG-019 is expected to be the first oral PAK4/NAMPT dual-target inhibitor of its kind for the treatment of NHL and advanced solid tumors, and is currently conducting phase 1 clinical trials of ATG-019 in Taiwan, China.
    ATG-017, which is acting on ERK1/2, has the best-in-class potential to treat hematosomas caused by multiple solid tumors and RAS-MAPK signaling pathological dysfunction, and is currently conducting Phase 1 clinical trials in Australia for the treatment of advanced solid tumors and hematosomas.
    not only that, Butge Pharmaceuticals has a number of preclinical drugs with great potential, including small molecule inhibitors ATG-018, which target co-dysfunctional capillary dilation and Rad3-related (ATR) kinases, and the new PD-L1/CD137 (4-1BB) ) dual-specific antibody ATG-101, humanized IgG1 monoclonal antibody ATG-022 for human Claudin 18.2 antigens, and KRAS G12C inhibitor ATG-012 for KRAS tumor proteins, etc.
    strong research and development, the future will form a business team because Deqi Pharmaceuticals has not yet made a profit from product sales, so the company has continued to lose money in recent years.
    2018 and 2019, Deqi Pharmaceuticals lost $146 million and $324 million, respectively.
    as of June 30, 2020, Deqi Pharmaceuticals' losses amounted to 538 million yuan, up 406 percent year-on-year.
    of these, research and development spending is a major reason for the loss, in 2018 and 2019, Deqi Pharmaceutical research and development expenditure of 116 million yuan, in 2020 the company increased investment in research and development, research and development spending in the first half of the year has reached 170 million yuan.
    images from the prospectus's current 53-member research and development team, with experience in different types of lymphoma, leukemia and multiple myeloma drugs, are expected to expand to more than 100 by 2023.
    in collaboration with industry-leading CRO and CDMO companies, Deqi Pharmaceuticals fully optimizes the effectiveness and efficiency of its drug development efforts, focusing on the development of blood and cancer treatment-related products.
    In terms of marketing, Deqi Pharmaceuticals expects to establish a 50-strong business team in 2021 to prepare for the ATG-010 (selinexor) or upcoming launch, and to form a full-time sales team of about 100 full-time within two years to promote sales of the ATG-010, which is expected to first cover about 100 large hospitals in China.
    commercialization of Dechi pharmaceutical products may not take long, with nine ongoing clinical trials and eight planned start-ups.
    41% of the funds raised will be allocated to ATG-010 and ATG-008 core products, and 25% will be allocated to ATG-016, ATG-527, AtG-019 and ATG-017, the four clinical stages of drug candidate research and development activities and related matters, 9% will be used for other preclinical drug candidates for preclinical and clinical research, 14% will be used to expand the research and development pipeline.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.